<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04353882</url>
  </required_header>
  <id_info>
    <org_study_id>MOROCCO-II</org_study_id>
    <nct_id>NCT04353882</nct_id>
  </id_info>
  <brief_title>Mu Opioid Receptor 1 Expression and Activation Patterns in Colorectal Cancer</brief_title>
  <official_title>Evaluation of the Difference in Expression of the Mu Type 1 Opioid Receptor and of the Markers of Its Activation (Cyclic Adenosine Monophosphate and Protein Kinase A) in Colorectal Cancer. Case-control Study in Patients With Tumor Recurrence Versus Disease-free Patients at 5 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario La Fe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario La Fe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational case-control study in a retrospective cohort of patients with stage II or III
      colorectal cancer undergoing scheduled surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational case-control study in a retrospective cohort of patients with stage II or III
      colorectal cancer undergoing scheduled surgery. Period January 2010-December 2014. Patients
      must have had at least 5 years of follow-up to define disease-free survival. From the cohort
      of patients previously studied in our center by immunohistochemistry, 31 we will select 10
      cases with recurrence by random sampling and we will match 10 controls by leveling the
      propensity score (propensity score matching).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MOR-1 expression by polymerase chain reaction (RT-qPCR) in tumor tissue and adjacent healthy tissue.</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer-free survival 5 years after surgery (disease-free survival-DFS).</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of MOR-1 activation measured by immunohistochemistry through cAMP and PKA levels.</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MOR-1 expression by immunohistochemistry in tumor tissue and adjacent healthy tissue.</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Use of halogenated vs intravenous hypnotic agent</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Carcinoembryonic antigen</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cancer antigen</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Neoadjuvant or adjuvant chemotherapy or radiation therapy</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Surgery time</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Surgery date</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hospital discharge</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Surgery complications</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Type of surgery</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ASA test</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Concomitant Diseases</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Colorectal Surgery for Stage II / III Primary Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>patients with tumor recurrence</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with-out tumor recurrence</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assess the difference in MOR-1 expression between healthy and tumor tissue</intervention_name>
    <description>Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.</description>
    <arm_group_label>patients with tumor recurrence</arm_group_label>
    <arm_group_label>patients with-out tumor recurrence</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing scheduled colorectal surgery for stage II and III primary colorectal
        cancer during the period 01/01/2010 and 12/31/2014.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years of age.

          -  Colorectal surgery scheduled between January 2010 - December 2014.

          -  Stage II or III colon or rectum neoplasm (T3 / T4 N + M0).

        Exclusion Criteria:

          -  Neoplasia of colon or rectum in Stage I or Stage IV.

          -  Non-oncological colorectal surgery.

          -  Urgent surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>May 17, 2020</last_update_submitted>
  <last_update_submitted_qc>May 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario La Fe</investigator_affiliation>
    <investigator_full_name>Oscar Diaz-Cambronero</investigator_full_name>
    <investigator_title>Principal Investigator of Anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

